These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 7481849

  • 1. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ.
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [Abstract] [Full Text] [Related]

  • 2. Synergistic interaction between cisplatin and gemcitabine in vitro.
    Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ.
    Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ.
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy studies with gemcitabine.
    van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ.
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
    [Abstract] [Full Text] [Related]

  • 5. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJ, Vermorken JB, Postmus PE, Peters GJ.
    Biochem Pharmacol; 1999 Feb 15; 57(4):407-15. PubMed ID: 9933029
    [Abstract] [Full Text] [Related]

  • 6. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
    Padrón JM, van Moorsel CJ, Bergman AM, Smitskamp-Wilms E, van der Wilt CL, Peters GJ.
    Anticancer Drugs; 1999 Jun 15; 10(5):445-52. PubMed ID: 10477163
    [Abstract] [Full Text] [Related]

  • 7. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.
    Int J Oncol; 2006 Jan 15; 28(1):237-44. PubMed ID: 16328001
    [Abstract] [Full Text] [Related]

  • 8. Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
    Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ.
    Semin Oncol; 1995 Aug 15; 22(4 Suppl 11):42-6. PubMed ID: 7481844
    [Abstract] [Full Text] [Related]

  • 9. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ.
    Eur J Cancer; 2000 Oct 15; 36(15):1974-83. PubMed ID: 11000580
    [Abstract] [Full Text] [Related]

  • 10. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ.
    Biochem Pharmacol; 1994 Oct 07; 48(7):1327-39. PubMed ID: 7945430
    [Abstract] [Full Text] [Related]

  • 11. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP, Peters GJ.
    Semin Oncol; 1995 Aug 07; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [Abstract] [Full Text] [Related]

  • 12. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
    Bhalla K, Holladay C, Lutzky J, Ibrado AM, Bullock G, Jasiok M, Singh S.
    Gynecol Oncol; 1992 Apr 07; 45(1):32-9. PubMed ID: 1601333
    [Abstract] [Full Text] [Related]

  • 13. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
    Moufarij MA, Phillips DR, Cullinane C.
    Mol Pharmacol; 2003 Apr 07; 63(4):862-9. PubMed ID: 12644587
    [Abstract] [Full Text] [Related]

  • 14. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG.
    Cancer Res; 1999 Aug 01; 59(15):3671-6. PubMed ID: 10446980
    [Abstract] [Full Text] [Related]

  • 15. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
    Yang LY, Li L, Jiang H, Shen Y, Plunkett W.
    Clin Cancer Res; 2000 Mar 01; 6(3):773-81. PubMed ID: 10741696
    [Abstract] [Full Text] [Related]

  • 16. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
    Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM, Peters GJ.
    Int J Oncol; 2003 Jan 01; 22(1):201-7. PubMed ID: 12469205
    [Abstract] [Full Text] [Related]

  • 17. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, Kanemura M, Ohmichi M.
    J Ovarian Res; 2014 Apr 09; 7():38. PubMed ID: 24713296
    [Abstract] [Full Text] [Related]

  • 18. Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP).
    Gallo D, Fruscella E, Ferlini C, Apollonio P, Mancuso S, Scambia G.
    Int J Gynecol Cancer; 2006 Apr 09; 16(1):222-30. PubMed ID: 16445637
    [Abstract] [Full Text] [Related]

  • 19. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
    van Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, Lakerveld B, Van der Vijgh WJ, Giaccone G, Postmus PE, Peters GJ.
    Eur J Cancer; 2000 Dec 09; 36(18):2420-9. PubMed ID: 11094319
    [Abstract] [Full Text] [Related]

  • 20. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.
    Biochem Pharmacol; 2001 Jun 01; 61(11):1401-8. PubMed ID: 11331076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.